Diabetes, Vol 46, Issue 11 1725-1732, Copyright © 1997 by American Diabetes Association

ARTICLES

Release of incompletely processed proinsulin is the cause of the disproportionate proinsulinemia of NIDDM

SE Kahn and PA Halban
Department of Medicine, VA Puget Sound Health Care System and University of Washington, Seattle 98108, USA.

The production of insulin from proinsulin involves cleavage of intact proinsulin into proinsulin conversion intermediates by the processing of enzymes PC2 and PC3 before fully processed insulin is produced. Intact proinsulin and these conversion intermediates are measured in many immunoreactive insulin (IRI) assays, and therefore contribute to the absolute IRI measurement. The proportion of basal IRI made up of proinsulin (PI)-like molecules (PI/IRI) is increased in NIDDM. Whether stimulated IRI levels are similarly made up of disproportionately increased PI/IRI or whether the relative proportions of proinsulin and its conversion intermediates are altered has not been evaluated. An index of the efficiency of proinsulin processing within the pancreatic beta-cell can be achieved by measuring PI/IRI immediately following acute stimulation of beta-cell secretion, and then determining the proportion of intact proinsulin and proinsulin conversion intermediates contributing to circulating proinsulin-like molecules. In this study, we determined the PI/IRI levels under basal and arginine-stimulated conditions in 17 healthy and 16 NIDDM subjects; high-performance liquid chromatography (HPLC) was also performed in a subset of these subjects to measure the relative contribution of intact proinsulin and its conversion intermediates to total proinsulin-like molecules. In NIDDM subjects, levels of both basal (44.6 +/- 9.6 vs. 9.3 +/- 1.5 pmol/l; P = 0.0007) and stimulated (64.0 +/- 12.7 vs. 19.8 +/- 2.8 pmol/l; P = 0.001) proinsulin-like molecules were higher than in healthy subjects. Although IRI was higher in NIDDM than in control subjects under basal conditions (106 +/- 19 vs. 65.1 +/- 8.1 pmol/l; P = 0.05), it was lower in NIDDM than in control subjects following stimulation (increment: 257 +/- 46 vs. 416 +/- 51 pmol/l; P = 0.03). PI/IRI ratios were increased in NIDDM subjects under both basal (43.3 +/- 5.0 vs. 14.0 +/- 1.3%; P < 0.0001) and stimulated (increment: 10.1 +/- 2.1 vs. 2.5 +/- 0.2%; P = 0.0006) conditions, compatible with the release of a disproportionately increased amount of proinsulin-like products. HPLC analysis revealed that, in the stimulated state, intact proinsulin made up 40.1 +/- 6.7% of proinsulin-like molecules in NIDDM individuals (n = 9) and 30.1 +/- 5.6% in healthy subjects (n = 7; NS). The remainder of the proinsulin-like molecules comprised the des-31,32-split proinsulin conversion intermediate. The increase in PI/IRI in NIDDM under basal and especially under stimulated conditions suggests that proinsulin conversion is indeed perturbed in this disorder. Because the relative proportions of intact and des-31,32-split proinsulin are similar in both healthy and NIDDM subjects, the orderly cleavage of proinsulin at its two junctions appears preserved. However, at the time of exocytosis, the secretory granule in the islet of NIDDM subjects contains an increased proportion of incompletely processed proinsulin, presumably reflecting a slower rate of conversion or granules' reduced time of residence in beta-cells.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				M. R. Rickels, H. W. Collins, A. Naji, G. T. Westermark, O. Korsgren, and P. Westermark Amyloid and Transplanted Islets N. Engl. J. Med., December 18, 2008; 359(25): 2729 - 2731. [Full Text] [PDF]

				H. E. Bates, A. Sirek, M. A. Kiraly, J. T. Y. Yue, M. C. Riddell, S. G. Matthews, and M. Vranic Adaptation to intermittent stress promotes maintenance of {beta}-cell compensation: comparison with food restriction Am J Physiol Endocrinol Metab, October 1, 2008; 295(4): E947 - E958. [Abstract] [Full Text] [PDF]

				H. Lu, Y. Yang, E. M. Allister, N. Wijesekara, and M. B. Wheeler The Identification of Potential Factors Associated with the Development of Type 2 Diabetes: A Quantitative Proteomics Approach Mol. Cell. Proteomics, August 1, 2008; 7(8): 1434 - 1451. [Abstract] [Full Text] [PDF]

				J. M. Lachin, C. A. Christophi, S. L. Edelstein, D. A. Ehrmann, R. F. Hamman, S. E. Kahn, W. C. Knowler, D. M. Nathan, and on behalf of the DPP Research Group Factors Associated With Diabetes Onset During Metformin Versus Placebo Therapy in the Diabetes Prevention Program Diabetes, April 1, 2007; 56(4): 1153 - 1159. [Abstract] [Full Text] [PDF]

				N. Kashemsant and C. B Chan Impact of uncoupling protein-2 overexpression on proinsulin processing J. Mol. Endocrinol., December 1, 2006; 37(3): 517 - 526. [Abstract] [Full Text] [PDF]

				L. Marzban, C. J. Rhodes, D. F. Steiner, L. Haataja, P. A. Halban, and C. B. Verchere Impaired NH2-Terminal Processing of Human Proislet Amyloid Polypeptide by the Prohormone Convertase PC2 Leads to Amyloid Formation and Cell Death. Diabetes, August 1, 2006; 55(8): 2192 - 2201. [Abstract] [Full Text] [PDF]

				D. A. Elder, R. L. Prigeon, R. P. Wadwa, L. M. Dolan, and D. A. D'Alessio {beta}-Cell Function, Insulin Sensitivity, and Glucose Tolerance in Obese Diabetic and Nondiabetic Adolescents and Young Adults J. Clin. Endocrinol. Metab., January 1, 2006; 91(1): 185 - 191. [Abstract] [Full Text] [PDF]

				L. Marzban, G. Trigo-Gonzalez, and C. B. Verchere Processing of Pro-Islet Amyloid Polypeptide in the Constitutive and Regulated Secretory Pathways of {beta} Cells Mol. Endocrinol., August 1, 2005; 19(8): 2154 - 2163. [Abstract] [Full Text] [PDF]

				The Diabetes Prevention Program Research Group Role of Insulin Secretion and Sensitivity in the Evolution of Type 2 Diabetes in the Diabetes Prevention Program: Effects of Lifestyle Intervention and Metformin Diabetes, August 1, 2005; 54(8): 2404 - 2414. [Abstract] [Full Text] [PDF]

				J. F. Paulsson and G. T. Westermark Aberrant Processing of Human Proislet Amyloid Polypeptide Results in Increased Amyloid Formation Diabetes, July 1, 2005; 54(7): 2117 - 2125. [Abstract] [Full Text] [PDF]

				L. Marzban, G. Soukhatcheva, and C. B. Verchere Role of Carboxypeptidase E in Processing of Pro-Islet Amyloid Polypeptide in {beta}-Cells Endocrinology, April 1, 2005; 146(4): 1808 - 1817. [Abstract] [Full Text] [PDF]

				M. E. Roder and S. E. Kahn Suppression of Beta-Cell Secretion by Somatostatin Does Not Fully Reverse the Disproportionate Proinsulinemia of Type 2 Diabetes Diabetes, December 1, 2004; 53(suppl_3): S22 - S25. [Abstract] [Full Text] [PDF]

				K. Gwinn-Hardy and V. Dawson Genomics-Proteomics and Stroke: Introduction Stroke, November 1, 2004; 35(11_suppl_1): 2731 - 2734. [Full Text] [PDF]

				R. L. Hull, G. T. Westermark, P. Westermark, and S. E. Kahn Islet Amyloid: A Critical Entity in the Pathogenesis of Type 2 Diabetes J. Clin. Endocrinol. Metab., August 1, 2004; 89(8): 3629 - 3643. [Abstract] [Full Text] [PDF]

				B. Zethelius, C. N. Hales, H. O. Lithell, and C. Berne Insulin Resistance, Impaired Early Insulin Response, and Insulin Propeptides as Predictors of the Development of Type 2 Diabetes: A population-based, 7-year follow-up study in 70-year-old men Diabetes Care, June 1, 2004; 27(6): 1433 - 1438. [Abstract] [Full Text] [PDF]

				K. B. Degn, C. B. Juhl, J. Sturis, G. Jakobsen, B. Brock, V. Chandramouli, J. Rungby, B. R. Landau, and O. Schmitz One Week's Treatment With the Long-Acting Glucagon-Like Peptide 1 Derivative Liraglutide (NN2211) Markedly Improves 24-h Glycemia and {alpha}- and {beta}-Cell Function and Reduces Endogenous Glucose Release in Patients with Type 2 Diabetes Diabetes, May 1, 2004; 53(5): 1187 - 1194. [Abstract] [Full Text] [PDF]

				A. Pfutzner, T. Kunt, C. Hohberg, A. Mondok, S. Pahler, T. Konrad, G. Lubben, and T. Forst Fasting Intact Proinsulin Is a Highly Specific Predictor of Insulin Resistance in Type 2 Diabetes Diabetes Care, March 1, 2004; 27(3): 682 - 687. [Abstract] [Full Text] [PDF]

				F. Bacha, R. Saad, N. Gungor, and S. A. Arslanian Adiponectin in Youth: Relationship to visceral adiposity, insulin sensitivity, and {beta}-cell function Diabetes Care, February 1, 2004; 27(2): 547 - 552. [Abstract] [Full Text] [PDF]

				L. Marzban, G. Trigo-Gonzalez, X. Zhu, C. J. Rhodes, P. A. Halban, D. F. Steiner, and C. B. Verchere Role of {beta}-Cell Prohormone Convertase (PC)1/3 in Processing of Pro-Islet Amyloid Polypeptide Diabetes, January 1, 2004; 53(1): 141 - 148. [Abstract] [Full Text] [PDF]

				G. Perseghin, A. Caumo, C. Arcelloni, S. Benedini, R. Lanzi, E. Pagliato, L. P. Sereni, G. Testolin, A. Battezzati, G. Comi, et al. Contribution of Abnormal Insulin Secretion and Insulin Resistance to the Pathogenesis of Type 2 Diabetes in Myotonic Dystrophy Diabetes Care, July 1, 2003; 26(7): 2112 - 2118. [Abstract] [Full Text] [PDF]

				P. A. Halban and J.-C. Irminger Mutant Proinsulin That Cannot Be Converted Is Secreted Efficiently from Primary Rat beta -Cells via the Regulated Pathway Mol. Biol. Cell, March 1, 2003; 14(3): 1195 - 1203. [Abstract] [Full Text] [PDF]

				D. Chin, S. E. Oberfield, M. E. Silfen, D. J. McMahon, A. M. Manibo, D. Accili, and L. S. Levine Proinsulin in Girls: Relationship to Obesity, Hyperinsulinemia, and Puberty J. Clin. Endocrinol. Metab., October 1, 2002; 87(10): 4673 - 4677. [Abstract] [Full Text] [PDF]

				C. C. Jensen, M. Cnop, R. L. Hull, W. Y. Fujimoto, S. E. Kahn, and the American Diabetes Association GENNID Study Gro {beta}-Cell Function Is a Major Contributor to Oral Glucose Tolerance in High-Risk Relatives of Four Ethnic Groups in the U.S. Diabetes, July 1, 2002; 51(7): 2170 - 2178. [Abstract] [Full Text] [PDF]

				A. J.G. Hanley, G. McKeown-Eyssen, S. B. Harris, R. A. Hegele, T. M.S. Wolever, J. Kwan, and B. Zinman Association of Parity With Risk of Type 2 Diabetes and Related Metabolic Disorders Diabetes Care, April 1, 2002; 25(4): 690 - 695. [Abstract] [Full Text] [PDF]

				A. J.G. Hanley, R. D'Agostino Jr., L. E. Wagenknecht, M. F. Saad, P. J. Savage, R. Bergman, and S. M. Haffner Increased Proinsulin Levels and Decreased Acute Insulin Response Independently Predict the Incidence of Type 2 Diabetes in the Insulin Resistance Atherosclerosis Study Diabetes, April 1, 2002; 51(4): 1263 - 1270. [Abstract] [Full Text] [PDF]

				N. G. Knowles, M. A. Landchild, W. Y. Fujimoto, and S. E. Kahn Insulin and Amylin Release Are Both Diminished in First-Degree Relatives of Subjects With Type 2 Diabetes Diabetes Care, February 1, 2002; 25(2): 292 - 297. [Abstract] [Full Text] [PDF]

				A. J. G. Hanley, G. McKeown-Eyssen, S. B. Harris, R. A. Hegele, T. M. S. Wolever, J. Kwan, and B. Zinman Cross-Sectional and Prospective Associations between Abdominal Adiposity and Proinsulin Concentration J. Clin. Endocrinol. Metab., January 1, 2002; 87(1): 77 - 83. [Abstract] [Full Text] [PDF]

				J. J. Meier, K. Hucking, J. J. Holst, C. F. Deacon, W. H. Schmiegel, and M. A. Nauck Reduced Insulinotropic Effect of Gastric Inhibitory Polypeptide in First-Degree Relatives of Patients With Type 2 Diabetes Diabetes, November 1, 2001; 50(11): 2497 - 2504. [Abstract] [Full Text] [PDF]

				P. A. Halban, S. E. Kahn, A. Lernmark, and C. J. Rhodes Gene and Cell-Replacement Therapy in the Treatment of Type 1 Diabetes: How High Must the Standards Be Set? Diabetes, October 1, 2001; 50(10): 2181 - 2191. [Abstract] [Full Text]

				S. E. Kahn The Importance of {beta}-Cell Failure in the Development and Progression of Type 2 Diabetes J. Clin. Endocrinol. Metab., September 1, 2001; 86(9): 4047 - 4058. [Full Text] [PDF]

				E. Krampl, N. A. Kametas, P. Nowotny, M. Roden, and K. H. Nicolaides Glucose Metabolism in Pregnancy at High Altitude Diabetes Care, May 1, 2001; 24(5): 817 - 822. [Abstract] [Full Text]

				M. Stumvoll, A. Fritsche, N. Stefan, E. Hardt, and H. Häring Evidence against a Rate-Limiting Role of Proinsulin Processing for Maximal Insulin Secretion in Subjects with Impaired Glucose Tolerance and {beta}-Cell Dysfunction J. Clin. Endocrinol. Metab., March 1, 2001; 86(3): 1235 - 1239. [Abstract] [Full Text]

				J. Wang, J. Xu, J. Finnerty, M. Furuta, D. F. Steiner, and C. B. Verchere The Prohormone Convertase Enzyme 2 (PC2) Is Essential for Processing Pro-Islet Amyloid Polypeptide at the NH2-Terminal Cleavage Site Diabetes, March 1, 2001; 50(3): 534 - 539. [Abstract] [Full Text]

				C. D. Berdanier Diabetes and Nutrition: The Mitochondrial Part J. Nutr., February 1, 2001; 131(2): 344S - 353. [Abstract] [Full Text]

				G. Emilien, M. Ponchon, C. Caldas, O. Isacson, and J.-M. Maloteaux Impact of genomics on drug discovery and clinical medicine QJM, July 1, 2000; 93(7): 391 - 423. [Abstract] [Full Text] [PDF]

				M. E. Røder, R. S. Schwartz, R. L. Prigeon, and S. E. Kahn Reduced Pancreatic B Cell Compensation to the Insulin Resistance of Aging: Impact on Proinsulin and Insulin Levels J. Clin. Endocrinol. Metab., June 1, 2000; 85(6): 2275 - 2280. [Abstract] [Full Text]

				H. Larsson and B. Ahrén Relative Hyperproinsulinemia as a Sign of Islet Dysfunction in Women with Impaired Glucose Tolerance J. Clin. Endocrinol. Metab., June 1, 1999; 84(6): 2068 - 2074. [Abstract] [Full Text]

				K. Hostens, Z. Ling, C. Van Schravendijk, and D. Pipeleers Prolonged Exposure of Human {beta}-Cells to High Glucose Increases Their Release of Proinsulin during Acute Stimulation with Glucose or Arginine J. Clin. Endocrinol. Metab., April 1, 1999; 84(4): 1386 - 1390. [Abstract] [Full Text]

				K. Park and C. B. Verchere Identification of a Heparin Binding Domain in the N-terminal Cleavage Site of Pro-islet Amyloid Polypeptide. IMPLICATIONS FOR ISLET AMYLOID FORMATION J. Biol. Chem., May 11, 2001; 276(20): 16611 - 16616. [Abstract] [Full Text] [PDF]